8-K current report · filed Oct 23, 2026

Phathom Pharmaceuticals, Inc. (PHAT) 8-K Current Report: October 23, 2026

Item 8.01PHAT overview

Short answer

Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 8.01 (Other Events). BDR sued FDA over alleged refusal to accept an ANDA referencing VOQUEZNA tablets.

Phathom Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • BDR sued FDA over alleged refusal to accept an ANDA referencing VOQUEZNA tablets
  • FDA-recognized NCE exclusivity runs through May 3, 2032, supporting Phathom’s expected protection from generic competition
  • Adverse ruling could shorten exclusivity and allow earlier FDA review or approval of competing ANDAs
  • Litigation creates potential risks to VOQUEZNA sales, stock price, management focus and financial prospects

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Phathom Pharmaceuticals, Inc. 8-K filings

Get the next PHAT 8-K as it lands

Follow PHAT for push alerts, or ask the research agent what this filing means.